Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 25024 | 245 | 36.3 | 89% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | EGF POLYMORPHISM | Author keyword | 3 | 100% | 1% | 3 |
| 2 | GEFITINIB THERAPY | Author keyword | 1 | 100% | 1% | 2 |
| 3 | INTRON 1 POLYMORPHISM | Author keyword | 1 | 100% | 1% | 2 |
| 4 | MOL ONCOL CI | Address | 1 | 50% | 1% | 2 |
| 5 | AC REPEAT | Author keyword | 1 | 50% | 0% | 1 |
| 6 | AVERAGE GENE COPY NUMBER | Author keyword | 1 | 50% | 0% | 1 |
| 7 | BIOINFORMAT SIGNALLING UNIT | Address | 1 | 50% | 0% | 1 |
| 8 | GC BOX BINDING FACTOR | Author keyword | 1 | 50% | 0% | 1 |
| 9 | GENET TRANSLAT MED PREVENT | Address | 1 | 50% | 0% | 1 |
| 10 | GRP ONCOL MOL | Address | 1 | 50% | 0% | 1 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | EGF POLYMORPHISM | 3 | 100% | 1% | 3 | Search EGF+POLYMORPHISM | Search EGF+POLYMORPHISM |
| 2 | GEFITINIB THERAPY | 1 | 100% | 1% | 2 | Search GEFITINIB+THERAPY | Search GEFITINIB+THERAPY |
| 3 | INTRON 1 POLYMORPHISM | 1 | 100% | 1% | 2 | Search INTRON+1+POLYMORPHISM | Search INTRON+1+POLYMORPHISM |
| 4 | AC REPEAT | 1 | 50% | 0% | 1 | Search AC+REPEAT | Search AC+REPEAT |
| 5 | AVERAGE GENE COPY NUMBER | 1 | 50% | 0% | 1 | Search AVERAGE+GENE+COPY+NUMBER | Search AVERAGE+GENE+COPY+NUMBER |
| 6 | GC BOX BINDING FACTOR | 1 | 50% | 0% | 1 | Search GC+BOX+BINDING+FACTOR | Search GC+BOX+BINDING+FACTOR |
| 7 | LINKER SCANNING | 1 | 50% | 0% | 1 | Search LINKER+SCANNING | Search LINKER+SCANNING |
| 8 | PLASMA EGF | 1 | 50% | 0% | 1 | Search PLASMA+EGF | Search PLASMA+EGF |
| 9 | PROGNOSTIC ESTIMATES | 1 | 50% | 0% | 1 | Search PROGNOSTIC+ESTIMATES | Search PROGNOSTIC+ESTIMATES |
| 10 | R497K | 1 | 50% | 0% | 1 | Search R497K | Search R497K |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | EGF GENE | 35 | 72% | 11% | 28 |
| 2 | SP1 RECOGNITION SITE | 8 | 75% | 2% | 6 |
| 3 | INTRON 1 POLYMORPHISM | 8 | 46% | 5% | 13 |
| 4 | 61 G A | 8 | 100% | 2% | 5 |
| 5 | 5UTR VARIANT A61G | 6 | 100% | 2% | 4 |
| 6 | A61G POLYMORPHISM | 6 | 100% | 2% | 4 |
| 7 | POLYMORPHIC SEQUENCE | 6 | 100% | 2% | 4 |
| 8 | INTRON 1 | 5 | 19% | 9% | 22 |
| 9 | R497K POLYMORPHISM | 4 | 75% | 1% | 3 |
| 10 | EGFR GENE | 4 | 25% | 5% | 13 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
|---|---|---|---|---|
| EGF +61A > G polymorphism and gastrointestinal cancer risk: A HuGE review and meta-analysis | 2013 | 7 | 30 | 43% |
| EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity | 2012 | 7 | 75 | 25% |
| Polymorphisms to Predict Outcome to the Tyrosine Kinase Inhibitors Gefitinib, Erlotinib, Sorafenib and Sunitinib | 2012 | 4 | 58 | 29% |
| Association of epidermal growth factor receptor (EGFR) gene polymorphism with lung cancer risk: a systematic review | 2014 | 0 | 12 | 42% |
| Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet | 2010 | 5 | 42 | 24% |
| Lack of association between EGF+61A > G polymorphism and melanoma susceptibility in Caucasians: A HuGE review and meta-analysis | 2013 | 0 | 20 | 30% |
| Modulation of EGFR gene transcription by secondary structures, a polymorphic repetitive sequence and mutations - a link between genetics and epigenetics | 2000 | 39 | 74 | 23% |
| Clinical Pharmacogenetics in Oncology: the Paradigm of Molecular Targeted Therapies | 2010 | 5 | 84 | 12% |
| Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity | 2005 | 0 | 44 | 16% |
| INVITRO TRANSCRIPTION OF EPIDERMAL GROWTH-FACTOR RECEPTOR GENE | 1991 | 1 | 15 | 33% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | MOL ONCOL CI | 1 | 50% | 0.8% | 2 |
| 2 | BIOINFORMAT SIGNALLING UNIT | 1 | 50% | 0.4% | 1 |
| 3 | GENET TRANSLAT MED PREVENT | 1 | 50% | 0.4% | 1 |
| 4 | GRP ONCOL MOL | 1 | 50% | 0.4% | 1 |
| 5 | HEBEI GEN HOSP | 1 | 50% | 0.4% | 1 |
| 6 | HOSP UNIV SAO PAULO | 1 | 50% | 0.4% | 1 |
| 7 | MA MIGLIAVACCA LIVER DIS | 1 | 50% | 0.4% | 1 |
| 8 | PSYCHIAT PEDIAT HUMAN GENET | 1 | 50% | 0.4% | 1 |
| 9 | SPORE LUNG CANC | 1 | 50% | 0.4% | 1 |
| 10 | SERV ENDOSCOPIAS | 0 | 33% | 0.4% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000179701 | BREAST CARCINOMA CELL LINE//BIOTINYLATED EPIDERMAL GROWTH FACTOR//BREAST CANCER BIOPSIES |
| 2 | 0.0000130599 | NIMOTUZUMAB//H R3//CETUXIMAB |
| 3 | 0.0000128380 | VEGF POLYMORPHISMS//VEGF POLYMORPHISM//RS2010963 |
| 4 | 0.0000126617 | FLIGHTLESS I//TTYH1//TWEETY |
| 5 | 0.0000118127 | GEFITINIB//ERLOTINIB//EGFR MUTATION |
| 6 | 0.0000112728 | IMMUNOGENE//MED MOLEC BIOL SHINJUKU KU//ERBB PROTEINS |
| 7 | 0.0000111974 | FAMILIAL GLIOMA//RTEL1//EVANSTON KELLOGG CANC CARE |
| 8 | 0.0000110624 | HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2//ADVANCED METASTATIC DISEASE//ANTI EGF RECEPTOR ANTIBODY |
| 9 | 0.0000083185 | PAPER CAPILLARY PERMEATION ADSORPTION//SEPARATABILITY//APRC |
| 10 | 0.0000079951 | ASTROGLIAL CELL CULTURES//NEUROSTATIN//ERBB1 |